Please ensure Javascript is enabled for purposes of website accessibility

Why Altimmune Stock Is Under Pressure Today

By Cory Renauer – Sep 28, 2021 at 11:17AM

Key Points

  • This morning, Altimmune reported phase 1 clinical trial data for its lead asset, pemvidutide, that shows it significantly reduced patients' weight after 12 weeks.
  • The stock is under pressure because one of the patients treated with pemvidutide, formerly ALT-801, exhibited signs of liver damage.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

What happened

Shares of Altimmune (ALT 8.44%) dropped nearly 30% when the market opened on Tuesday. Investors are reacting to safety issues presented along with positive efficacy results for the company's lead candidate. Some of the losses have since been recovered, and the biotech stock was down 20.6% as of 10:46 a.m. EDT on Tuesday.

So what 

This morning, Altimmune revealed 12-week data from a phase 1 clinical trial with the company's lead candidate, pemvidutide, formerly known as ALT-801. This is a dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor agonist designed to treat obesity.

Depressed investor looking at a downward sloping stock chart.

Image source: Getty Images.

The study randomized 34 volunteers to receive one of three ascending doses of pemvidutide or a placebo. On average, patients who received the mid-size pemvidutide dose lost more than 19 pounds, or around 10.3% of their body weight.

The response exhibited might be strong enough to compete with successful new weight-loss drugs such as Saxenda and Wegovy from Novo Nordisk (NVO 1.23%). Unfortunately, one of the patients experienced elevated levels of liver enzymes that quickly resolved after a pause in dosing.

Now what

One case of elevated liver enzymes might not seem like a big deal, but it would make selling this drug nearly impossible. That's because pemvidutide is intended for long-term use by people who are relatively healthy.

Having to go up against pharmaceutical giants like Novo Nordisk with a treatment that requires physicians to frequently monitor patients for elevated liver enzymes is an uphill battle Altimmune isn't cut out for. Investors can hope this was an isolated incident, but it's probably best to watch this stock from a safe distance until we have a lot more data to look at.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Stocks Mentioned

$10.79 (8.44%) $0.84
Novo Nordisk Stock Quote
Novo Nordisk
$126.13 (1.23%) $1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.